Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Other financing activities: 2016-2023

Historic Other financing activities for Spyre Therapeutics (SYRE) over the last 5 years, with Jun 2023 value amounting to $1.8 million.

  • Spyre Therapeutics' Other financing activities fell 12.00% to $1.8 million in Q2 2023 from the same period last year, while for Jun 2023 it was $6.5 million, marking a year-over-year decrease of 22.14%. This contributed to the annual value of $7.1 million for FY2022, which is 11.53% down from last year.
  • According to the latest figures from Q2 2023, Spyre Therapeutics' Other financing activities is $1.8 million, which was up 3.86% from $1.7 million recorded in Q1 2023.
  • Spyre Therapeutics' 5-year Other financing activities high stood at $2.1 million for Q3 2021, and its period low was $1.1 million during Q1 2019.
  • Its 3-year average for Other financing activities is $1.9 million, with a median of $1.9 million in 2022.
  • As far as peak fluctuations go, Spyre Therapeutics' Other financing activities surged by 36.15% in 2020, and later slumped by 31.85% in 2022.
  • Spyre Therapeutics' Other financing activities (Quarterly) stood at $1.2 million in 2019, then soared by 36.15% to $1.6 million in 2020, then climbed by 29.90% to $2.1 million in 2021, then plummeted by 31.85% to $1.4 million in 2022, then decreased by 12.00% to $1.8 million in 2023.
  • Its last three reported values are $1.8 million in Q2 2023, $1.7 million for Q1 2023, and $1.4 million during Q4 2022.